Drug Profile
Cx 611
Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix NV; Cx611; eASC - TiGenixLatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Cellerix
- Developer TiGenix
- Class Antirheumatics; Antiseptics; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Cytokine modulators; Immunomodulators; Inflammation mediator inhibitors; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Rheumatoid arthritis
- No development reported Sepsis
Most Recent Events
- 30 Dec 2022 No development reported - Phase-I/II for Sepsis in Belgium (IV)
- 30 Dec 2022 No development reported - Phase-I/II for Sepsis in France (IV)
- 30 Dec 2022 No development reported - Phase-I/II for Sepsis in Lithuania (IV)